Lexaria Bioscience (LEXX) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Lexaria Bioscience is set to explore a new frontier with its DehydraTECH-liraglutide, an oral version of the multi-billion dollar drug liraglutide, following promising results in animal studies. The company plans a human pilot study to compare its formulation against the injectable Saxenda® and aims to unlock potential revenue opportunities in the GLP-1 drug market. If successful, this could lead to further trials and expansion within this lucrative sector.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
